Premium
Persistent Vascular Remodeling and Leakiness are Important Components of the Pathobiology of Re‐bleeding in Hemophilic Joints: Two Informative Cases
Author(s) -
Kidder Wesley,
Chang Eric Y.,
M. Moran Colleen,
Rose Steven C.,
Drygalski Annette
Publication year - 2016
Publication title -
microcirculation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.793
H-Index - 83
eISSN - 1549-8719
pISSN - 1073-9688
DOI - 10.1111/micc.12273
Subject(s) - medicine , clotting factor , vascularity , hemostasis , angiography , surgery , vascular remodelling in the embryo , haemophilia , pathology
Objective It is unclear if vascular remodeling in hemophilic joints perpetuates bleeding because it is difficult to gauge leakiness in the setting of low clotting factor levels. Two patients provided the unique opportunity to demonstrate that vascular changes directly contribute to joint bleeding. Approach and Results Two patients had severe hemophilic arthropathies; joint vascularity and bleeding were studied during periods of normalized plasma clotting factor activities with MSKUS and PD. One patient was “cured” of hemophilia with liver transplantation. Abnormal elbow vascularization persisted despite normalization of coagulation status and was associated with severe bleeding years after transplant. Dynamic vascular changes were detected prior to and during bleeding; angiography revealed enlarged, thickened vessels consistent with remodeling, and required arterial embolization. The second patient had continued knee bleeding and fluctuating vascular changes for months following knee replacement, unresponsive to intense daily factor treatment. Subsequently, new bleeds developed in other joints associated with similar vascular changes despite continued factor replacement. Conclusions Vascular remodeling contributes to perpetuated hemophilic joint bleeding and therefore contributes to progressive arthropathy. Intra‐articular or systemic administration of anti‐angiogenic drugs, such as vascular endothelial growth factor antagonists, might be of benefit in such patients, but requires study.